ANAB
ANAPTYSBIO, INC
NASDAQ · Healthcare · Biotechnology · US
$55.20
+0.25%Next report
Analyst consensus
- Next report date
- Sep 23, 2026
- EPS estimate
- -$0.47
- Revenue estimate
- $14.1M
Latest reported
- Last report date
- May 12, 2026
- EPS actual
- -$1.84
- EPS estimate
- -$0.32
- Revenue actual
- $25.6M
- Revenue estimate
- $18.9M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -48.3%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $83
- PT range
- $70 – $95
- Analysts
- 2
2 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| May 12, 2026 | -$0.32 | -$1.84 | Miss -475.00% | $25.6M |
| Mar 3, 2026 | $0.89 | $1.58 | Beat 77.53% | $108.2M |
| Nov 4, 2025 | -$1.06 | $0.52 | Beat 149.06% | $76.3M |
| Feb 27, 2025 | -$1.61 | -$0.72 | Beat 55.28% | $43.1M |
| May 9, 2024 | -$1.54 | -$1.64 | Miss -6.49% | $7.2M |
| Mar 11, 2024 | -$1.74 | -$1.59 | Beat 8.62% | $9.0M |
| Nov 2, 2023 | -$1.72 | -$1.41 | Beat 18.02% | $3.3M |
| May 11, 2023 | -$1.04 | -$1.58 | Miss -51.92% | $1.4M |
| Mar 1, 2023 | -$0.92 | -$0.93 | Miss -1.09% | $6.8M |
| May 4, 2022 | -$0.87 | -$1.31 | Miss -50.57% | $970.0K |
| Mar 7, 2022 | $2.28 | -$1.13 | Miss -149.56% | $1.0M |
| Nov 4, 2021 | -$0.74 | -$0.24 | Beat 67.57% | $20.9M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 10, 2026